Shopping Cart
- Remove All
![TargetMol](https://newstatic.targetmol.com/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
2 mg | $87 | 5 days | |
25 mg | $652 | 6-8 weeks | |
50 mg | $847 | 6-8 weeks | |
100 mg | $1,390 | 6-8 weeks |
Description | Mavorixafor trihydrochloride is a selective and orally available CXCR4 antagonist (IC50: 13 nM against CXCR4 125I-SDF binding) and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs (IC50s: 1 and 9 nM). |
In vitro | Mavorixafor (AMD-070) shows no effect on other chemokine receptors (CCR1, CCR2b, CCR4, CCR5, CXCR1, and CXCR2) [1]. Mavorixafor (6.6 μM) significantly suppresses the anchorage-dependent growth, the migration and matrigel invasion of the B88-SDF-1 cells [2]. |
In vivo | Mavorixafor, at a dosage of 2 mg/kg administered orally, substantially decreases the count of metastatic lung nodules in mice while concurrently reducing the expression of human Alu DNA, all without causing loss in body weight [2]. |
Alias | AMD-070 trihydrochloride |
Molecular Weight | 458.86 |
Formula | C21H30Cl3N5 |
Cas No. | 2309699-17-8 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | ||||||||||||||||||||
Solubility Information | DMSO: 6 mg/mL (13.08 mM) | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.